Trials for Respiratory Virus Vaccine “Positive” By Investing.com
© Reuters. By Scott Kanowsky Investing.com — GlaxoSmithKline plc (LON:) has announced that its vaccine for respiratory syncytial virus for adults aged 60 and above showed overall efficacy of 82.6%, beating the results of a treatment […]
